{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:54:28Z","timestamp":1789239268174,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508105"],"award-info":[{"award-number":["2023YFC2508105"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373484"],"award-info":[{"award-number":["82373484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073447"],"award-info":[{"award-number":["82073447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003354"],"award-info":[{"award-number":["82003354"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82221002"],"award-info":[{"award-number":["82221002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130090"],"award-info":[{"award-number":["82130090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003362"],"award-info":[{"award-number":["82003362"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>New interleukin (IL)-17A inhibitors seem to demonstrate smaller effects on tuberculosis (TB) reactivation than expected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the risk of TB reactivation, to assess serial interferon (IFN)-\u03b3 levels, and to weigh up the risks and benefits of TB chemoprophylaxis in patients with psoriasis treated with IL-17A inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This dual-centre study included patients with psoriasis who were treated with IL-17A inhibitors. The incidence of active TB, serial IFN-\u03b3 levels tested by IFN-\u03b3 release assays (IGRAs), adverse events (AEs) and effectiveness were evaluated through 1\u2005year in patients with psoriasis treated with IL-17A inhibitors. According to the chemoprophylaxis treatment regimen, patients with latent TB infection (LTBI) were classified into three groups: a complete chemoprophylaxis dose regimen (CCP), an incomplete chemoprophylaxis (ICCP) or no chemoprophylaxis (NCP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 220 IGRA-negative patients, 17 of 220 (7.3%) became IGRA positive after receiving a mean of 69.1 weeks of IL-17A inhibitor treatment. Only one case of new-onset TB was observed after 52 weeks of ixekizumab therapy. Significant changes in IFN-\u03b3 levels were observed in IGRA-negative patients. Similarly, IFN-\u03b3 levels [listed as the mean (SD)] significantly increased at 1\u2005year compared with baseline among IGRA-positive patients in the NCP [105 (68.7) vs. 236 (80.8) pg mL\u22121, P &amp;lt; 0.01] and ICCP [75.3 (48.3) vs. 608 (249) pg mL\u22121, P &amp;lt; 0.001] groups, whereas the changes were not significant [125 (26.6) vs. 131 (21.7) pg mL\u22121, P = 0.70] in the CCP group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>During IL-17A inhibitor therapy, there is a need for increased awareness of annual screening and assessment of individual risk for early detection of TB infection. LTBI treatment is generally well tolerated and is effective in preventing increased IFN-\u03b3 responses in patients with psoriasis treated with IL-17A inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae549","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T12:17:32Z","timestamp":1738585052000},"page":"1107-1115","source":"Crossref","is-referenced-by-count":6,"title":["Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China"],"prefix":"10.1093","volume":"50","author":[{"given":"Kun","family":"Hu","sequence":"first","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University , Changsha, Hunan ,","place":["China"]},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology , Changsha, Hunan ,","place":["China"]},{"name":"Furong Laboratory , Changsha, Hunan ,","place":["China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0465-2829","authenticated-orcid":false,"given":"Yizhang","family":"Liu","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University , Changsha, Hunan ,","place":["China"]},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology , Changsha, Hunan ,","place":["China"]},{"name":"Furong Laboratory , Changsha, Hunan ,","place":["China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sha","sequence":"additional","affiliation":[{"name":"Dalian Dermatosis Hospital , Dalian, Liaoning ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University , Changsha, Hunan ,","place":["China"]},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology , Changsha, Hunan ,","place":["China"]},{"name":"Furong Laboratory , Changsha, Hunan ,","place":["China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7701-3649","authenticated-orcid":false,"given":"Lu","family":"Jian","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University , Changsha, Hunan ,","place":["China"]},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology , Changsha, Hunan ,","place":["China"]},{"name":"Furong Laboratory , Changsha, Hunan ,","place":["China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Duan","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University , Changsha, Hunan ,","place":["China"]},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology , Changsha, Hunan ,","place":["China"]},{"name":"Furong Laboratory , Changsha, Hunan ,","place":["China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Lv","sequence":"additional","affiliation":[{"name":"Dalian Dermatosis Hospital , Dalian, Liaoning ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Kuang","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University , Changsha, Hunan ,","place":["China"]},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology , Changsha, Hunan ,","place":["China"]},{"name":"Furong Laboratory , Changsha, Hunan ,","place":["China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital , Changsha, Hunan ,","place":["China"]},{"name":"Xiangya Clinical Research Center for Cancer Immunotherapy, Central South University , Changsha, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"Suppl. 1","key":"2025052303170682200_llae549-B1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","article-title":"Global Tuberculosis Report 2020 \u2013 reflections on the global TB burden, treatment and prevention efforts","volume":"113","author":"Chakaya","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"Suppl. 1","key":"2025052303170682200_llae549-B2","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.ijid.2022.03.011","article-title":"The WHO Global Tuberculosis 2021 Report \u2013 not so good news and turning the tide back to end TB","volume":"124","author":"Chakaya","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025052303170682200_llae549-B3","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLOS Med"},{"key":"2025052303170682200_llae549-B4","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1038\/emi.2016.10","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements","volume":"5","author":"Ai","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"2025052303170682200_llae549-B5","doi-asserted-by":"crossref","DOI":"10.5070\/D3249041425","article-title":"Tuberculosis and interleukin blocking monoclonal antibodies: is there risk?","volume":"24","author":"Kelsey","year":"2018","journal-title":"Dermatol Online J"},{"key":"2025052303170682200_llae549-B6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris \u2013 part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052303170682200_llae549-B7","first-page":"e152","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections","volume-title":"Clin Transl Immunol","author":"Kammuller","year":"2017"},{"key":"2025052303170682200_llae549-B8","doi-asserted-by":"crossref","first-page":"8909834","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"key":"2025052303170682200_llae549-B9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052303170682200_llae549-B10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jaad.2020.06.012","article-title":"No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis","volume":"83","author":"Mrowietz","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025052303170682200_llae549-B11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025052303170682200_llae549-B12","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/jdv.19406","article-title":"No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: multicenter case series of 35 patients","volume":"38","author":"Manzanares","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052303170682200_llae549-B13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1684\/ejd.2020.3909","article-title":"Safety of secukinumab in psoriasis patients with latent tuberculosis infection","volume":"30","author":"Machado","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2025052303170682200_llae549-B14","doi-asserted-by":"crossref","first-page":"e14512","DOI":"10.1111\/dth.14512","article-title":"Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study","volume":"33","author":"Shu","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025052303170682200_llae549-B15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis \u2013 time for a paradigm change","volume":"35","author":"Nogueira","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052303170682200_llae549-B16","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1111\/jdv.18131","article-title":"Active tuberculosis in a cohort of patients with psoriasis on biologic therapy: learnings from real-life medical practice","volume":"36","author":"Lopez-Trujillo","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025052303170682200_llae549-B17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2025052303170682200_llae549-B18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025052303170682200_llae549-B19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5\u2005years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025052303170682200_llae549-B20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s12879-022-07539-4","article-title":"Spatio-temporal distribution of tuberculosis and the effects of environmental factors in China","volume":"22","author":"Li","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025052303170682200_llae549-B21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12889-020-10055-2","article-title":"Tuberculosis-related stigma and its determinants in Dalian, Northeast China: a cross-sectional study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Public Health"},{"key":"2025052303170682200_llae549-B22","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.3390\/ijerph18136778","article-title":"Spatiotemporal patterns of tuberculosis in Hunan Province, China","volume":"18","author":"Alene","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2025052303170682200_llae549-B23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1365-2133.2008.08457.x","article-title":"QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy","volume":"158","author":"Desai","year":"2008","journal-title":"Br J Dermatol"},{"key":"2025052303170682200_llae549-B24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12879-021-06141-4","article-title":"Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose\u2013response meta-regression analysis","volume":"21","author":"Ledesma","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025052303170682200_llae549-B25","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/rheumatology\/kead315","article-title":"Prevalence of LTBI in patients with autoimmune diseases and accuracy of IGRA in predicting TB relapse","volume":"62","author":"Chandrashekara","year":"2023","journal-title":"Rheumatology (Oxford"},{"key":"2025052303170682200_llae549-B26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.puhe.2022.10.003","article-title":"Prevalence and risk factors of latent tuberculosis infection among college students: a systematic review and meta-analysis","volume":"213","author":"Yuan","year":"2022","journal-title":"Public Health"},{"key":"2025052303170682200_llae549-B27","doi-asserted-by":"crossref","first-page":"1051060","DOI":"10.3389\/fcimb.2023.1051060","article-title":"Positive rate and risk factors of latent tuberculosis infection among persons living with HIV in Jiangsu Province, China","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2025052303170682200_llae549-B28","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jiph.2023.10.009","article-title":"Prevalence and factors associated with tuberculosis infection in India","volume":"16","author":"Selvaraju","year":"2023","journal-title":"J Infect Public Health"},{"key":"2025052303170682200_llae549-B29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.arcmed.2015.03.009","article-title":"Associated risk factors for latent tuberculosis infection in subjects with diabetes","volume":"46","author":"Mart\u00ednez-Aguilar","year":"2015","journal-title":"Arch Med Res"},{"key":"2025052303170682200_llae549-B30","doi-asserted-by":"crossref","first-page":"e1004099","DOI":"10.1371\/journal.ppat.1004099","article-title":"Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection","volume":"10","author":"Gopal","year":"2014","journal-title":"PLOS Pathog"},{"key":"2025052303170682200_llae549-B31","first-page":"e92973","article-title":"Interleukin-17 limits hypoxia-inducible factor 1\u03b1 and development of hypoxic granulomas during tuberculosis","volume-title":"JCI Insight","author":"Domingo-Gonzalez","year":"2017"},{"key":"2025052303170682200_llae549-B32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","article-title":"IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-\u03b3 responses if IL-12p70 is available","volume":"175","author":"Khader","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"2025052303170682200_llae549-B33","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/1346-8138.16471","article-title":"Risk of tuberculosis infection and serial changes in interferon-\u03b3 release assays in elderly patients with psoriasis receiving biologic therapy","volume":"49","author":"Koo","year":"2022","journal-title":"J Dermatol"},{"key":"2025052303170682200_llae549-B34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/thoraxjnl-2013-204229","article-title":"Cigarette smoke impairs cytokine responses and BCG containment in alveolar macrophages","volume":"69","author":"van Zyl-Smit","year":"2014","journal-title":"Thorax"},{"key":"2025052303170682200_llae549-B35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cyto.2016.03.009","article-title":"Effect of IFN-\u03b3, IL-12 and IL-10 cytokine production and mRNA expression in tuberculosis patients with diabetes mellitus and their household contacts","volume":"81","author":"Meenakshi","year":"2016","journal-title":"Cytokine"},{"key":"2025052303170682200_llae549-B36","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s13555-022-00745-7","article-title":"The tuberculosis positive conversion rate among psoriasis patients treated with adalimumab and secukinumab: a single-center retrospective study in China","volume":"12","author":"Xiao","year":"2022","journal-title":"Dermatol Ther (Heidelb"},{"key":"2025052303170682200_llae549-B37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tube.2007.01.002","article-title":"Plasma granulysin levels and cellular interferon-\u03b3 production correlate with curative host responses in tuberculosis, while plasma interferon-\u03b3 levels correlate with tuberculosis disease activity in adults","volume":"87","author":"Sahiratmadja","year":"2007","journal-title":"Tuberculosis (Edinb)"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae549\/61792570\/llae549.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1107\/61792570\/llae549.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1107\/61792570\/llae549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:17:18Z","timestamp":1747984638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/6\/1107\/8005182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae549","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,7]]}}}